Skeletal MusclePhysiologyPeer-reviewed journal article
Functional and structural pathologies in skeletal muscle of a rat model of Duchenne muscular dystrophy
Young Il LeeiD, Cora C. Hart, C. Spencer Henley‐BeasleyiD, Jeffrey S Herr, Eli Zerpa, Elisabeth R. BartoniD, David W. HammersiD, Hugh Lee SweeneyiD
Abstract
BackgroundDuchenne muscular dystrophy (DMD) is a lethal pediatric degenerative muscle disease for which there is no cure. Robust preclinical models that recapitulate major clinical features of DMD are required to investigate efficacy of potential DMD therapeutics. Rat models of DMD have emerged as promising small animal models to accomplish this; however, there have been no comprehensive studies investigating the functional skeletal muscle decrements associated with the modeling of DMD in rats. MethodsCRISPR/Cas9 gene editing was used to generate a dystrophin-deficient Sprague-Dawley muscular dystrophy rat (MDR). Biochemical and immunofluorescent analyses were performed to confirm loss of dystrophin in striated muscles of this rat model. In situ and ex vivo muscle function was assessed in wild-type (WT) and MDR muscles at 3, 6, and 12 months of age, followed by histopathological analyses. ResultsMDR muscle tissues exhibited loss of full-length dystrophin and reduced content of other dystrophin glycoprotein complex members. MDR extensor digitorum longus (EDL) muscles and diaphragms displayed pronounced and progressive muscle weakness beginning at 3 months of age, compared to WT littermates. EDLs also exhibit susceptibility to eccentric contraction-induced damage. Functional deficits in soleus muscles were less severe and were associated with a right shift in force-frequency relationship and a muscle fiber-type shift. MDR muscles display progressive histopathology including degenerative lesions, fibrosis, regenerative foci, and modest adipose deposition. ConclusionsMDR is a preclinical model of DMD that exhibits many translational features of the human disease, including a large dynamic range of muscle decrements, that has high utility for the evaluation of potential therapeutics for DMD.
- Citations
- 1
- FWCI
- 2.07
- Field percentile
- top 18%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A NEW DYSTROPHIN DEFICIENT RAT MODEL MIRRORING EXON SKIPPING IN PATIENTS WITH DMD EXON 45 DELETIONS
Tao Wang, Cynthia Daoud, … Isabelle Richard·Disease Models & MechanismsPeer-reviewed·Jan 1, 2026
- Four new Duchenne muscular dystrophy mouse models with clinically relevant exon deletions in the human DMD gene
Maaike van Putten, Margot M. L. Linssen, … Peter Hohenstein·Disease Models & MechanismsPeer-reviewed·Aug 1, 2026
- Generation and characterisation of mouse models of Duchenne Muscular Dystrophy (DMD)
Jayshen Arudkumar, Yu Chinn Joshua Chey, … Fatwa Adikusuma·BMC MethodsPeer-reviewed·Dec 9, 2024
- Desmin is a modifier of dystrophic muscle features in Mdx mice
A. Ferry, J. Messeant, … O. Agbulut·bioRxiv·Aug 23, 2019
- The D2-mdx mouse as a preclinical model for Duchenne muscular dystrophy: a natural history study across two independent sites
Paola Mantuano, Antonietta Mele, … Maaike van Putten·bioRxiv·Jul 12, 2026
- Lifespan analysis of dystrophic mdx fast-twitch muscle morphology and its impact on contractile function
L. Kiriaev, S. Kueh, … S. I. Head·bioRxiv·Sep 7, 2021